SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : RAINFOREST CAFE
RAIN 3.569-9.1%Jan 12 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Marshall Teitelbaum who wrote (894)10/3/1996 1:12:00 AM
From: Dennis Vail   of 4704
 
Marshall,

I checked out you posts at ATIS and my question is what's the worst case scenario here.If FDA doesn't give ATIS the greenlight on dermagraft,then they go back to testing and one of their competitors sews up the market in the meantime?So where do you place ATIS market value without dermagraft?$6-$8?And if there is more testing to do what's chances they can get back before the FDA before the competition gets a comparable product approved?In other words,if they miss how far would the stock have to drop before you'd buy some more?

Personally,I think the analyst is just covering his rear end.This way either way it goes he can say "told you so!"(the stategy and tactics of a small night animal).

Regards,
Dennis

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News